Big Blue launches drug research tech; GSK drug falls short in breast cancer study;

 @FierceBiotech: Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Story | Follow @FierceBiotech

 @RyanMFierce: Some upbeat Ph2 data in breast cancer from Puma Biotech, which licensed the drug from Pfizer in October. Release | Follow @RyanMFierce

 @MaureenFierce: Reading: The loss of the middle (drugs and the people who find them). Story by @Dereklowe | Follow @MaureenFierce

 @MarkHFierce: But is the FDA bill an overall improvement? Curious what people think. | Follow @MarkHFierce

 @FierceMedDev: Recently profiled them. Bluegrass Vascular starts 1st clinical study of the Surfacer inside-out access catheter system. Release | Follow @FierceMedDev

> IBM has debuted a software that can quickly generate data on drug compounds and patents, after working for years on the tech with drugmakers such as Pfizer ($PFE), AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY). Article

> GlaxoSmithKline ($GSK) reported that its drug Tykerb failed to achieve its primary goal in a Phase III study involving patients with early cases of breast cancer. Article

> In a release that says "For media outside of the U.S. only," German drugmaker Boehringer Ingelheim reports that it has randomized the final patient in its Phase III trial of the oral protease inhibitor BI 201335 for treating chronic hepatitis C virus. The drug is being tested in combination with interferon. Release

> Furiex Pharmaceuticals ($FURX) fell short of the primary endpoint of its Phase II trial of the drug PPD-10558 in patients with statin-associated myalgia, prompting the developer to scrap the program. Release

> Aiming to advance interferon-free treatments for hepatitis C virus, Vertex Pharmaceuticals ($VRTX) and partner Alios BioPharma has started two Phase I studies of Alios' nucleotide analogs ALS-2200 and ALS-2158. Item

Pharma News

 @FiercePharma: New issues at Ben Venue--J&J's CMO on Doxil--highlight pitfalls of contract manufacturing, WSJ reports. Piece | Follow@FiercePharma

> Doxil supplier cited again by FDA inspectors. Item

> FDA panel wants label change for Yaz, Yasmin. Story

> Pfizer settles hormone-drug suit after $72.6M jury award. Article

> Tykerb, Avastin suffer disappointing data at SABCS. News

> Reuters: Bidders unlikely to meet Rottapharm's $2.7B price. Report

And Finally... Biotech VC Bruce Booth provides some insider insights into why it might not be a good idea for investors to walk away from struggling startups. Blog post